VI
RPRX icon

Versor Investments’s Royalty Pharma RPRX Stock Holding History

Versor Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,942
Closed -$236K – 955
2024
Q2 		$236K Sell
8,942
-30,617
-77% -$849K 0.04% 610
2024
Q1 		$1.2M Buy
39,559
+18,517
+88% +$546K 0.24% 103
2023
Q4 		$591K Buy
+21,042
New +$578K 0.12% 278
2023
Q3 		– Sell
-33,813
Closed -$1.04M – 820
2023
Q2 		$1.04M Buy
33,813
+11,013
+48% +$373K 0.18% 76
2023
Q1 		$821K Sell
22,800
-9,990
-30% -$370K 0.11% 166
2022
Q4 		$1.3M Buy
32,790
+13,490
+70% +$563K 0.11% 88
2022
Q3 		$775K Buy
+19,300
New +$824K 0.05% 308
2022
Q2 		– Sell
-7,746
Closed -$302K – 903
2022
Q1 		$302K Sell
7,746
-2,036
-21% -$79.9K 0.01% 485
2021
Q4 		$390K Buy
+9,782
New +$380K 0.01% 328

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versor Investments's RPRX Position: Q3 2024 in Review

Versor Investments sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 8,942 shares — an estimated $236K sold.

Versor Investments first reported a position in RPRX in Q4 2021 and held it in 9 quarters. The position peaked at $1.3M in Q4 2022. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Versor Investments reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Versor Investments sold 8,942 Royalty Pharma shares in Q3 2024, an estimated $236K.
  • Versor Investments first reported a position in Royalty Pharma in Q4 2021 and held it in 9 quarters.
  • Versor Investments's Royalty Pharma position peaked at $1.3M in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Versor Investments's 13F filing for Q3 2024, filed 4 Nov 2024.